Background; Noninvasive ventilation (NIV) is commonly used in various critical care settings across a variety of aetiologies of acute respiratory failure (ARF). For hypercapnic respiratory failure, mainly consequent to COPD exacerbation, (NIV) can be used at an early stage to prevent intubation, at a later stage as an alternative to first-line endotracheal intubation, or as a means to facilitate weaning, Aim and objectives; to characterize a large population of coronavirus disease 2019 patients with hypoxemic respiratory failure receiving (NIV) inside the intensive care unit (ICU), and to detect the risk of mortality for patients requiring intubation, Patients and methods; This Retrospective study was conducted at Zagazig Chest Hospital from June 2020 to June 2021. The study included 120 patients with acute respiratory failure due to Covid 19 infection confirmed by CT chest findings and PCR for Covid 19, Result; Duration of NIV was ranged between 4 hours – 21 days with mean value 6.00±3.956 days. Outcome show that 32(26.67%) were improved and transferred to ward and 88(73.33%) were died. Duration of MV was ranged between 1 –7 days with mean value 3.46±2.025 days. Duration of staying in ICU was ranged between 2 –21 days with mean value 7.54±4.476 days, Conclusion; NIV could be useful respiratory support to prevent silent hypoxia as a complication of COVID -19. Also, NIV in COVID -19 patients with severe pneumonia was associated with high mortality rates. Keywords; Noninvasive ventilation (NIV), acute respiratory failure (ARF) and coronavirus disease 2019 (COVID-19).